Innovation Spotlight: Revolutionizing Vascular Access

We are thrilled to spotlight a groundbreaking advancement in medical technology developed by Vascular Pathways, Inc. The company’s recently issued patent for the “Intravenous catheter insertion and blood sample devices and method of use” (Patent No. 12,589,225) represents a massive leap forward in patient care. This cutting-edge invention seamlessly coordinates the movement of an access needle, a coaxial intravenous catheter, and a flexible safety guidewire to drastically improve insertion success rates, particularly in patients with fragile, tortuous, or difficult-to-locate vessels.

The invention is exceptionally innovative because it introduces a partially automated mechanism for guidewire-assisted IV placement. By integrating a sliding tracking member, a built-in bleed-back indicator, and a safety wire that automatically transitions to a coiled configuration inside the vessel, the device virtually eliminates accidental needle sticks, minimizes blood spatter, and prevents painful double-punctures. The precision embedded into this all-in-one tool reduces clinical complications, ensuring that healthcare providers can administer fluids, draw blood, and deliver medications safely and efficiently.

May 2026 Patent of the Month

It is no surprise that this remarkable technology has been named the Patent of the Month for the Pharma-Medical-Devices-Healthcare Industry for May 2026. Recognizing its profound impact on standardizing clinical care, the industry committee awarded this honor to Vascular Pathways, Inc. for directly addressing one of the most common—yet complication-prone—procedures in modern medicine. By blending mechanical automation with intuitive physical design, this catheter device protects both the practitioner and the patient, significantly reducing healthcare-associated infections and elevating the gold standard for peripheral venous access globally.

R&D Tax Credit Eligibility in the USA

From a financial and business strategy perspective, the practical applications and iterative development of this patent make it a prime candidate for the Research and Development (R&D) Tax Credit in the United States. Under Section 41 of the Internal Revenue Code, companies that invest in resolving technological uncertainties through experimentation can claim significant tax incentives. The engineering efforts required to design the automated guidewire mechanism, the development of prototype blood-detection sensors, and the rigorous clinical testing necessary to refine the device’s safety features all qualify as targeted research activities. By continually testing and improving these complex electromechanical components to achieve FDA compliance and superior clinical outcomes, companies developing similar medical devices can offset a substantial portion of their engineering, materials, and labor costs through the R&D tax credit.